Triboelectric Immunotherapy/Calcium Electroporation System for Synergistically Enhanced Tumor Therapy
Source abstract
Abstract
Abstract Calcium overload is a promising anticancer treatment that kills tumor cells primarily by causing mitochondrial dysfunction in cells. However, calcium overload therapy is limited by inefficient cellular uptake of Ca 2+ . Herein, a triboelectric immunotherapy/calcium electroporation (CaEP) synergistic tumor therapy is developed using electrostatic‐breakdown induced direct‐current (DC) generated by a triboelectric nanogenerator (TENG). In this work, an 8 × 10 cm TENG can generate approximately 5–30 pulsed DC with a peak output of 60 µA in a single sliding. The pulsed DC can not only directly damage tumor cells and activate T cells‐mediated adaptive immunity response to inhibit tumor growth (that is, triboelectric immunotherapy), but also promote the cellular uptake of Ca 2+ (increased up to 235.9% in vitro) by electroporation to improve the therapeutic effect of calcium overload tumor therapy. The triboelectric immunotherapy/CaEP treatment can increase IL‐12 and TNF‐α within the tumor tissue to 175.7% and 185.5%, respectively, illustrating the upregulation of immune‐promoting factor levels. Moreover, the adenosine triphosphate (ATP) leakage and high mobility group box 1 protein (HMGB1) release are also enhanced (increased to 211.2%, and 154.3%, respectively). This work offers an effective electrical‐assisted tumor therapy technique and provides proof of concept of this technique as a miniaturized tumor treatment system for solid tumors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Sensor and Energy Harvesting Materials · Microbial Inactivation Methods · MXene and MAX Phase Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopedics Trauma and Microsurgery Zhongnan Hospital of Wuhan University School of Pharmaceutical Sciences Wuhan University Wuhan 430071 China
Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE) Wuhan University Wuhan 430071 China
National Engineering Research Center for Nanomedicine College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 China
Funding
National Natural Science Foundation of China · China Postdoctoral Science Foundation
References (56)
Show source-provided references
1. 10.1038/s41568-018-0089-110.1038/s41568-018-0089-1 ↗
2. 10.1038/s41574-018-0115-010.1038/s41574-018-0115-0 ↗
3. 10.1002/anie.20231757810.1002/anie.202317578 ↗
4. 10.1016/j.chempr.2019.06.00310.1016/j.chempr.2019.06.003 ↗
5. 10.1016/j.biomaterials.2021.12108010.1016/j.biomaterials.2021.121080 ↗
6. 10.1016/j.jcis.2022.11.13710.1016/j.jcis.2022.11.137 ↗
7. 10.1021/acsami.1c1330410.1021/acsami.1c13304 ↗
8. 10.1016/j.apsb.2022.08.00810.1016/j.apsb.2022.08.008 ↗
9. 10.1002/adma.20231321210.1002/adma.202313212 ↗
10. 10.1016/j.biomaterials.2023.12230010.1016/j.biomaterials.2023.122300 ↗
11. 10.1016/j.neuroimage.2019.03.07710.1016/j.neuroimage.2019.03.077 ↗
12. Gibson W. · Cochrane Database Syst. Rev. · 2019 · 4
13. 10.1016/j.bjpt.2017.12.00510.1016/j.bjpt.2017.12.005 ↗
14. 10.1038/s41467-019-08782-110.1038/s41467-019-08782-1 ↗
15. 10.1002/adma.20231124610.1002/adma.202311246 ↗
16. 10.1021/acsnano.0c0702010.1021/acsnano.0c07020 ↗
17. 10.1200/JCO.2020.38.4_suppl.54110.1200/JCO.2020.38.4_suppl.541 ↗
18. 10.1021/acs.chemrev.1c0067710.1021/acs.chemrev.1c00677 ↗
19. Ahmed A. · Environ. Sci. · 2017 · 10 · 653
20. 10.1002/adma.20190279310.1002/adma.201902793 ↗
21. 10.1002/adma.20210956810.1002/adma.202109568 ↗
22. 10.1016/j.nanoen.2021.10600410.1016/j.nanoen.2021.106004 ↗
23. 10.1126/sciadv.aav643710.1126/sciadv.aav6437 ↗
24. 10.1002/admt.20210019510.1002/admt.202100195 ↗
25. 10.1016/j.mattod.2023.02.02610.1016/j.mattod.2023.02.026 ↗
26. 10.1016/j.nantod.2020.10099310.1016/j.nantod.2020.100993 ↗
27. 10.1038/s41392-023-01668-110.1038/s41392-023-01668-1 ↗
28. 10.1200/JCO.2019.37.4_suppl.37210.1200/JCO.2019.37.4_suppl.372 ↗
29. 10.1186/s12951-023-02083-y10.1186/s12951-023-02083-y ↗
30. 10.1002/aenm.20220181310.1002/aenm.202201813 ↗
31. 10.1002/adma.20220813910.1002/adma.202208139 ↗
32. 10.1007/s10439-005-9076-210.1007/s10439-005-9076-2 ↗
33. 10.1038/s41598-017-12960-w10.1038/s41598-017-12960-w ↗
34. 10.1016/j.biomaterials.2023.12228410.1016/j.biomaterials.2023.122284 ↗
35. 10.1016/j.bbrc.2013.05.01410.1016/j.bbrc.2013.05.014 ↗
36. 10.1146/annurev-biophys-052118-11545110.1146/annurev-biophys-052118-115451 ↗
37. 10.1021/acsnano.1c0276510.1021/acsnano.1c02765 ↗
38. 10.1073/pnas.200323611710.1073/pnas.2003236117 ↗
39. 10.4161/onci.2813110.4161/onci.28131 ↗
40. 10.1080/2162402X.2017.130133210.1080/2162402X.2017.1301332 ↗
41. 10.1016/j.bbcan.2009.08.00310.1016/j.bbcan.2009.08.003 ↗
42. 10.1155/2010/54616310.1155/2010/546163 ↗
43. 10.1146/annurev.pathol.1.110304.10021810.1146/annurev.pathol.1.110304.100218 ↗
44. 10.2174/15665240878376957110.2174/156652408783769571 ↗
45. 10.1158/0008-5472.CAN-11-378210.1158/0008-5472.CAN-11-3782 ↗
46. 10.3389/fonc.2020.0123510.3389/fonc.2020.01235 ↗
47. 10.1038/nature0829610.1038/nature08296 ↗
48. 10.1038/nri137210.1038/nri1372 ↗
49. 10.1021/acsnano.3c0259210.1021/acsnano.3c02592 ↗
50. 10.1016/j.immuni.2005.10.00110.1016/j.immuni.2005.10.001 ↗
51. 10.1016/j.bioactmat.2022.11.01110.1016/j.bioactmat.2022.11.011 ↗
52. 10.1038/3258810.1038/32588 ↗
53. 10.1016/j.jaci.2016.06.00310.1016/j.jaci.2016.06.003 ↗
54. 10.3390/cancers1111176310.3390/cancers11111763 ↗
55. 10.1002/ijc.3107110.1002/ijc.31071 ↗
56. 10.1158/0008-5472.CAN-16-161110.1158/0008-5472.CAN-16-1611 ↗